middle.news
Lumos Diagnostics Boosts Q3 Revenue 21% as Medicare Coverage Expands
6:20am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Lumos Diagnostics Boosts Q3 Revenue 21% as Medicare Coverage Expands
6:20am on Monday 2nd of June, 2025 AEST
Key Points
Q3 FY25 revenue rose 21% quarter-on-quarter to US$3.5 million
FebriDx sales growth and expanded Hologic development agreement
Medicare coverage secured in four US regions at $41.38 per test
FebriDx CLIA waiver study progressing with FDA application targeted for late 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Lumos Diagnostics (ASX:LDX)
OPEN ARTICLE